- Home
- ACHV vs MOLN Comparison
ACHV vs MOLN Comparison
Compare ACHV & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- MOLN
- Stock Information
- Founded
- ACHV N/A
- MOLN 2004
- Country
- ACHV United States
- MOLN Switzerland
- Employees
- ACHV N/A
- MOLN N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MOLN
- Sector
- ACHV Health Care
- MOLN
- Exchange
- ACHV Nasdaq
- MOLN Nasdaq
- Market Cap
- ACHV 167.6M
- MOLN 142.5M
- IPO Year
- ACHV N/A
- MOLN 2021
- Fundamental
- Price
- ACHV $4.93
- MOLN $4.03
- Analyst Decision
- ACHV Strong Buy
- MOLN Hold
- Analyst Count
- ACHV 1
- MOLN 1
- Target Price
- ACHV $12.00
- MOLN $4.00
- AVG Volume (30 Days)
- ACHV 2.4M
- MOLN 6.5K
- Earning Date
- ACHV 11-06-2025
- MOLN 10-30-2025
- Dividend Yield
- ACHV N/A
- MOLN N/A
- EPS Growth
- ACHV N/A
- MOLN N/A
- EPS
- ACHV N/A
- MOLN N/A
- Revenue
- ACHV N/A
- MOLN N/A
- Revenue This Year
- ACHV N/A
- MOLN N/A
- Revenue Next Year
- ACHV N/A
- MOLN $1,000.00
- P/E Ratio
- ACHV N/A
- MOLN N/A
- Revenue Growth
- ACHV N/A
- MOLN N/A
- 52 Week Low
- ACHV $1.84
- MOLN $3.36
- 52 Week High
- ACHV $5.78
- MOLN $6.24
- Technical
- Relative Strength Index (RSI)
- ACHV 63.71
- MOLN 57.67
- Support Level
- ACHV $4.77
- MOLN $3.72
- Resistance Level
- ACHV $5.42
- MOLN $4.72
- Average True Range (ATR)
- ACHV 0.44
- MOLN 0.18
- MACD
- ACHV -0.00
- MOLN 0.04
- Stochastic Oscillator
- ACHV 58.94
- MOLN 41.70
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.